Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is:
- To measure the ability of OSI-774 to effectively treat bronchioloalveolar cell lung
cancer.
- To see whether the use of OSI-774 provides meaningful symptomatic benefit in patients
with advanced bronchioloalveolar cell lung cancer.
This study is a Phase II study. The first study of OSI-774 was done to evaluate what dose
should be given to patients with cancer has been completed. The purpose of this research
study is to see whether this experimental treatment, called OSI-774, can cause a type of
non-small cell lung cancer to stop growing or shrink. This study is sponsored by a company
called Genentech, and is being done at Memorial Hospital, as well as other cancer centers
around the country interested in developing new drugs for the treatment of this type of
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Dana-Farber Cancer Institute Genentech, Inc. M.D. Anderson Cancer Center Northwestern University Vanderbilt-Ingram Cancer Center